scholarly journals Evaluation of usage of bone scan index in assessment of metastatic prostate cancer

2021 ◽  
Vol 12 (1) ◽  
pp. 20-26
Author(s):  
Halil Ćorović ◽  
Nusret Salkica ◽  
Safet Hadžimusić ◽  
Enis Tinjak ◽  
Adel Brčaninović
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Bone Scan ◽  
Imaging Biomarker ◽  
Diagnostic Tools ◽  
Therapeutic Effects ◽  
Male Population ◽  
Bone Scan Index ◽  
Scientific Review ◽  
Bone Changes

Introduction: Prostate cancer has been the leading type of cancer to affect male population, and as such, it is a subject to efforts to furthermore diagnostic tools already in existence as well as development of new ones which will Aid early diagnostic, treatments as well as a follow up procedures and clinical trials. Bone scan index is a useful and objective biomarker used as a valuable tool for determination as to precise bone involvement in advanced cases, as well as a tool to predict the outcome in prostate cancer patients in clinical trials.Methods: This paper is a non-experimental (qualitative) research, that is, a scientific review of the literature.Results: The results we analyzed in this paper were collected from published academic journals.Conclusion: As a new imaging biomarker, bone scan index has potential to predict therapeutic effects and survival of patients with prostate cancer. Using measurable diagnostic image parameters, the bone scan index is important for determining metastatic bone changes in prostate cancer patients.

scholarly journals Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy

2013 ◽  
Vol 3 (1) ◽  
pp. 9 ◽  
Author(s):  
Reza Kaboteh ◽  
Jan-Erik Damber ◽  
Peter Gjertsson ◽  
Peter Höglund ◽  
Milan Lomsky ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Bone Scan ◽  
Imaging Biomarker ◽  
Bone Scan Index ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Automated bone scan index as an imaging biomarker in metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16600-e16600
Author(s):  
Aseem Anand ◽  
Stephanie Daignault ◽  
Luke T. Nordquist ◽  
Jorge Ramos ◽  
Rohit K. Jain ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Scan ◽  
Imaging Biomarker ◽  
Castration Resistant Prostate Cancer ◽  
Bone Scan Index ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer

2012 ◽  
Vol 30 (5) ◽  
pp. 519-524 ◽  
Author(s):  
Elizabeth R. Dennis ◽  
Xiaoyu Jia ◽  
Irina S. Mezheritskiy ◽  
Ryan D. Stephenson ◽  
Heiko Schoder ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Metastatic Prostate Cancer ◽  
Univariate Analysis ◽  
Imaging Biomarker ◽  
Bone Scan Index ◽  
Risk Of Death ◽  
Percent Change ◽  
Castration Resistant

Purpose There is currently no imaging biomarker for metastatic prostate cancer. The bone scan index (BSI) is a promising candidate, being a reproducible, quantitative expression of tumor burden seen on bone scintigraphy. Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure. Patients and Methods We retrospectively examined serial bone scans from patients with castration-resistant metastatic prostate cancer (CRMPC) enrolled in four clinical trials. We calculated BSI at baseline and at 3 and 6 months on treatment and performed univariate and bivariate analyses of PSA, BSI, and survival. Results Eighty-eight patients were scanned, 81 of whom have died. In the univariate analysis, the log percent change in BSI from baseline to 3 and 6 months on treatment prognosticated for survival (hazard ratio [HR], 2.44; P = .0089 and HR, 2.54; P < .001, respectively). A doubling in BSI resulted in a 1.9-fold increase in risk of death. Log percent change in PSA at 6 months on treatment was also associated with survival (HR, 1.298; P = .013). In the bivariate analysis, change in BSI while adjusting for PSA was prognostic at 3 and 6 months on treatment (HR, 2.368; P = .012 and HR, 2.226; P = .002, respectively), but while adjusting for BSI, PSA was not prognostic. Conclusion These data furnish early evidence that on-treatment changes in BSI are a response indicator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC.

scholarly journals Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (48) ◽  
pp. 84449-84458 ◽  
Author(s):  
Dongyang Li ◽  
Hang Lv ◽  
Xuanyu Hao ◽  
Yudi Dong ◽  
Huixu Dai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Value ◽  
Bone Scan ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Imaging Biomarker ◽  
Bone Scan Index
Sign in / Sign up

Export Citation Format

Share Document